Nivalis Therapeutics Announces Results from Phase 2 Clinical Trial of Cavosonstat for
Treatment of Cystic Fibrosis
ir.nivalis.com/press-releases/detail/56
As of September 30, 2016, Nivalis has $66.2 million in cash and marketable securities. Nivalis has no outstanding debt and there are 15.5 million shares of common stock issued and outstanding
Cash/Share $4,26
ir.nivalis.com/press-releases/detail/54
Treatment of Cystic Fibrosis
ir.nivalis.com/press-releases/detail/56
As of September 30, 2016, Nivalis has $66.2 million in cash and marketable securities. Nivalis has no outstanding debt and there are 15.5 million shares of common stock issued and outstanding
Cash/Share $4,26
ir.nivalis.com/press-releases/detail/54